Paras Biopharmaceuticals Finland
@parasbiopharma.com
Paras Biopharmaceuticals Finland Oy Paras Finland (Europe) is a fast growing biopharmaceutical technology development company which has successfully developed the proprietary Diabrid Platform Technology for the high level expression of biosimilars and long therapeutic peptides in specially designed genetically stable clones. Paras Biopharmaceuticals Finland Oy is specialized in design, development and optimization of manufacturing technologies for therapeutic peptides and soon to be off patent biologics. The company is building a robust portfolio of proprietary technologies and has developed extensive intellectual property. Paras has developed multiple novel technologies, 1. Diabrid® Technology 2. NobleCleav®Technologies 3. Biomultifold® Technology 4. Cytoplasmic Protein Folding Technologies Key Highlights of Paras Collaboration • Paras Biopharmaceuticals Finland ( Europe) has Advanced Bio-technologies for Production of Biologics APIs – Mainly Analog Insulins, Osteoporosis (Teriparatide), and Rheumatoid Arthritis and Oncology products.
Paras Biopharmaceuticals Finland's Company Logos
Paras Biopharmaceuticals Finland's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#416E9E
San Marino
65, 110, 158
211, 42, 44
59, 30, 0, 38
#53BCEB
Picton Blue
83, 188, 235
199, 79, 62
65, 20, 0, 8
#0B1560
Arapawa
11, 21, 96
233, 79, 21
89, 78, 0, 62
About Paras Biopharmaceuticals Finland
Paras Biopharmaceuticals Finland Oy is an innovative biopharmaceutical technology development company. Established in 2012, it specializes in the development of biologics and biosimilar technologies. With a team of experienced scientists and technologists, Paras Biopharmaceuticals Finland Oy has successfully developed the Diabrid Platform Technology, a proprietary system for high-level expression of biosimilars in genetically stable clones.
Utilizing their expertise in biological processes and recombinant protein expression, Paras Biopharmaceuticals Finland Oy offers a range of products and services. Their Diabrid Technology enables scale-up production of biosimilar technologies in various therapeutic categories, including osteoporosis, rheumatoid arthritis, metabolic disorders (such as diabetes), and oncology. The company combines scientific excellence with advanced infrastructure capabilities to simplify product and process development.
Paras Biopharmaceuticals Finland Oy is committed to creating value and advancing healthcare through their innovative platform and cutting-edge solutions. They strive for excellence in quality and aim to make a positive impact in the biopharmaceutical industry
Company type
Privately Held
Year founded
2012
Company size
11-50 employees
